How to boost clinical trial access and make patients health-empowered
September 17, 2024 | Activated Patient, Inclusion, Patient Participation, Patient-centricity, Pharma, clinical trials
Clinical research is becoming more patient-centric, but there’s still more that needs to be done to make clinical trials available to everyone. This could include wider participation.
How to increase patient participation
Pharmaceutical companies are working on overturning this statistic by designing and building trials that centre around participant needs. This includes greater patient involvement in trial design; more opportunities for treatment at home; fewer tests and assessments; and new technologies for support and monitoring.
However, it seems clinical trial participation is not for everyone. Could it be because a huge amount of trust, awareness and understanding is needed to become a clinical trial participant?
Where the ‘activated’ patient comes in
According to health researcher Judith Hibbard, activated patients, who are actively engaged in managing their health and advocating for themselves, are better equipped to handle health conditions and contribute to treatment decisions.
Although, it’s not always an equal starting point because not everyone will be at activated status. Because initiatives often engage with those who are already activated and have high levels of health literacy, The complexity of clinical trial information means that some patients defer decision-making to their doctors. It may not be on purpose, but this excludes many from potentially life-changing medicines.
Empower patients through clinical trials
This may be an opportunity for those in charge of clinical trials to take a leading role in helping patients to become activated, creating a push-pull that works in all directions. Consider clinical trial education and awareness resources developed with everyone in mind, helping to bridge the knowledge gap and supporting people to make informed decisions for their own health.
Shift towards community-inclusive trials
The industry is already beginning to shift towards more patient-centred clinical trial recruitment and providing trial information that speaks to all. But that’s just the start. Perhaps it’s time to bring whole communities into contact with the clinical research world instead, giving everyone an opportunity to share their opinions and ideas —, a chance to feel part of something bigger.
It might not be easy, but it will be worth it.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Invited, but not equipped: patient involvement needs more than an open door
Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.
The outcomes are already chosen. So when can patients really shape them?
Explore why involving patients early in Joint Scientific Consultations is critical to shaping the outcomes measured in clinical trials.
Long-term clinical trial engagement is a behavioural challenge – not just an informational one
Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.
Patients are telling the truth — just not to you
Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.
When what matters to patients is hard to measure
Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
A seat at the table: what the EU HTA reforms really ask of patient involvement
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.
Why faster trials make participant understanding more important than ever
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
Older trial participants reject bad design, not technology
Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.
5 key takeaways from the Patient Centricity and Engagement Conference
Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.